This voice is automatically generated. Please let us know if you have one. feedback.
Although sales of products related to COVID-19 decreased, the growth in US pharmaceutical spending in 2023 was on an upward trend.
Overall spending on medicines in the United States slowed to 2.5%, but when COVID-19 vaccines and treatments are taken out of consideration, the growth rate jumped to 9.9%, the report said. Annual trend report Graduated from IQVIA Human Data Science Institute.
Pharmaceutical spending increased by $10.4 billion in 2023. This was partially driven by a shift to new brands and higher priced medicines. IQVIA also predicts continued growth over the next five years, with manufacturers’ expected net revenues expected to increase by 4% to 7% despite potential losses from patent expirations and patent expirations. I am. inflation control law.
“Oncology and obesity will drive growth until 2028,” the report states.
However, other areas such as diabetes, immunology, and COVID-19 are expected to further drag on that forward momentum.
“The market growth rate of 9.9% is comparable to the growth rate in 2015 during the early adoption of hepatitis C treatment, which has only been surpassed in recent years through 2021, when spending increased due to the first year of COVID-19 vaccine rollout. That’s true.” Go to report summary.
Here are five notable trends that are impacting the way Americans take drugs.
Immunology growth may stall
Drugs that alter the body’s immune response have become powerful treatments for many major disease categories in recent years, with 22 new drugs introduced in the United States in the past decade alone. This powerful drug category is driven by blockbuster drugs such as: humirais the best-selling drug in history, with daily doses increasing by 60% from 2019 to 2023.
However, overall spending on immunotherapy is ready to change This is because more drugs in this category will fall off the patent cliff and the advent of biosimilars will slow spending growth to 2% to 5% through 2028.
Spending on new treatments such as cell therapy, gene therapy and RNA therapy also increased last year. IQVIA estimates that this type of therapy will bring in $18 billion in revenue by 2028.
Important points for daily use
45%
The increase in days used for obesity drugs in 2023 is the largest increase of any treatment category on the list.
12%
The increase in the use of immunotherapy is primarily driven by new agents.
15%
Contraceptive pill use is decreasing and being replaced by on-demand permanent surgical options.
Rapid increase in antibiotic use raises concerns about antimicrobial resistance
Bacterial infections will return to pre-pandemic levels in 2023, increasing antibiotic use, a troubling trend that could lead to more bacterial infections. drug-resistant insects. Especially among her children under 19 years of age, bacterial infections and antibiotic use decreased significantly during the pandemic, she said, by 50% below the pre-pandemic average through the second quarter of 2021. But the numbers have rebounded. Antibiotic prescriptions were 4% above the baseline in the last quarter of 2023.
Adults 65 and older also increased their antibiotic use during the same quarter, increasing by 12% from baseline, likely due to a sharp rise in invasive streptococcal infections in that group.
More expensive drugs are coming onto the market
The mix of medicines patients use is changing, with a market shift toward more expensive drug options totaling $22 billion in 2023, according to IQVIA.
“In general, products with higher daily costs, especially on a net basis, are products with higher clinical value, and as a result, this positive growth in spending mix means more patients are using better drugs. “The results show that
Approval of new indications for existing drugs in large therapeutic areas such as oncology and immunology and drug shifts based on fresh clinical evidence are often behind many of the changes seen in this area.
Biosimilar intake is almost increasing
Many lucrative drugs are losing patent rights and biosimilars are starting to eat up a larger portion of the market. However, not all biosimilars are successful.
“Less than a third of the total amount of biologics are molecules containing biosimilars, and their uptake is has changed considerably intermolecularly,” the report states. “To date, biosimilars account for 23% of the number of treatment days compared to competing molecules. The penetration rate for biosimilars that have been on the market for at least three years has increased from 8% for insulin lispro. 82% for bevacizumab.”
Humira’s FDA-approved duck products have made slow progress, accounting for just 2% of sales at the end of last year. Differences in prescriptions and insurance contracts that are loyal to Humira are among the factors hindering its widespread use. But other drugs are also performing well, such as Lucentis’ biosimilar, which had 45% market share at the end of 2023.
“The wide range of intake patterns increases the level of uncertainty for biosimilar manufacturers, purchasers, and policy makers in this area,” the report said.
Weight loss drugs fuel the growth of illegal pharmacies
Another troubling trend is the proliferation of illegal online pharmacies. Online pharmacies often sell counterfeit medicines, and since 2019, sales have increased by 47%. Currently, the best-selling drug on the illicit market is his GLP-1 inhibitor.as a manufacturer rush to catch up With the demand for prescriptions, more people are looking for other buyers.Cybersecurity company recently went down 250 websites Selling counterfeit drugs like Ozempic.
“If patients are getting what could be a counterfeit version of a company’s product, that’s clearly a problem,” said Michael Kleinrock, principal research director at IQVIA’s Human Data Science Institute. “The importance of this issue is greater than the actual scale of this illegal online pharmacy prescribing, which is approximately 2% of the growing prescription volume.”
